BSE Live
Mar 19, 16:01Prev. Close
4822.85
Open Price
4750.00
Bid Price (Qty.)
4706.00 (3)
Offer Price (Qty.)
4732.05 (8)
NSE Live
Mar 19, 15:48Prev. Close
4818.00
Open Price
4784.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
4724.50 (10)
| Balance Sheet of Pfizer (in Rs. Cr.) | Nov 04 | |
| 12 mths | ||
| EQUITIES AND LIABILITIES | ||
| SHAREHOLDER'S FUNDS | ||
| Equity Share Capital | 28.80 | |
| Total Share Capital | 28.80 | |
| Reserves and Surplus | 312.92 | |
| Total Reserves and Surplus | 312.92 | |
| Total Shareholders Funds | 341.72 | |
| NON-CURRENT LIABILITIES | ||
| Long Term Borrowings | 0.00 | |
| Deferred Tax Liabilities [Net] | 7.06 | |
| Other Long Term Liabilities | 0.00 | |
| Long Term Provisions | 0.00 | |
| Total Non-Current Liabilities | 7.06 | |
| CURRENT LIABILITIES | ||
| Short Term Borrowings | 12.00 | |
| Trade Payables | 96.39 | |
| Other Current Liabilities | 16.45 | |
| Short Term Provisions | 54.21 | |
| Total Current Liabilities | 179.05 | |
| Total Capital And Liabilities | 528.87 | |
| ASSETS | ||
| NON-CURRENT ASSETS | ||
| Tangible Assets | 71.55 | |
| Intangible Assets | 0.16 | |
| Capital Work-In-Progress | 3.94 | |
| Other Assets | 0.00 | |
| Fixed Assets | 75.64 | |
| Non-Current Investments | 3.24 | |
| Deferred Tax Assets [Net] | 13.41 | |
| Long Term Loans And Advances | 0.00 | |
| Other Non-Current Assets | 60.07 | |
| Total Non-Current Assets | 152.37 | |
| CURRENT ASSETS | ||
| Current Investments | 0.00 | |
| Inventories | 73.89 | |
| Trade Receivables | 71.73 | |
| Cash And Cash Equivalents | 161.10 | |
| Short Term Loans And Advances | 69.77 | |
| OtherCurrentAssets | 0.00 | |
| Total Current Assets | 376.50 | |
| Total Assets | 528.87 | |
| OTHER ADDITIONAL INFORMATION | ||
| CONTINGENT LIABILITIES, COMMITMENTS | ||
| Contingent Liabilities | 52.53 | |
| CIF VALUE OF IMPORTS | ||
| Raw Materials | 31.78 | |
| Stores, Spares And Loose Tools | 0.00 | |
| Trade/Other Goods | 0.00 | |
| Capital Goods | 0.31 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||
| Expenditure In Foreign Currency | 6.83 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||
| Dividend Remittance In Foreign Currency | 8.64 | |
| EARNINGS IN FOREIGN EXCHANGE | ||
| FOB Value Of Goods | 3.77 | |
| Other Earnings | 20.29 | |
| BONUS DETAILS | ||
| Bonus Equity Share Capital | 19.11 | |
| NON-CURRENT INVESTMENTS | ||
| Non-Current Investments Quoted Market Value | -- | |
| Non-Current Investments Unquoted Book Value | 3.24 | |
| CURRENT INVESTMENTS | ||
| Current Investments Quoted Market Value | -- | |
| Current Investments Unquoted Book Value | -- |
10.02.2026
Pfizer Standalone December 2025 Net Sales at Rs 645.03 crore, up 19.9% Y-o-Y
13.11.2025
Pfizer Standalone September 2025 Net Sales at Rs 642.34 crore, up 9.13% Y-o-Y
20.05.2025
Pfizer Standalone March 2025 Net Sales at Rs 591.91 crore, up 8.28% Y-o-Y
01.02.2025
Pfizer Standalone December 2024 Net Sales at Rs 537.99 crore, down 0.37% Y-o-Y
19.10.2016
05.08.2016
03.01.2014
10.01.2011
19.03.2026
19.03.2026
18.03.2026
18.03.2026
MFs boost healthcare exposure, turn overweight on earnings recovery and valuations
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth